William Blair & Company
PTLA

William Blair & Company’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

William Blair & Company’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,200
Closed -$58K – 1621
2017
Q4 		$58K Buy
1,200
+800
+200% +$40.5K ﹤0.01% 1332
2017
Q3 		$22K Sell
400
-1,700
-81% -$99.8K ﹤0.01% 1342
2017
Q2 		$118K Hold
2,100
– – ﹤0.01% 1414
2017
Q1 		$82K Sell
2,100
-3,900
-65% -$124K ﹤0.01% 1303
2016
Q4 		$134K Buy
+6,000
New +$117K ﹤0.01% 1192

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

William Blair & Company's PTLA Position: Q2 2020 in Review

William Blair & Company sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 116,433 shares — an estimated $830K sold.

William Blair & Company first reported a position in PTLA in Q2 2016 and held it in 16 quarters. The position peaked at $4.8M in Q1 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • William Blair & Company reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • William Blair & Company sold 116,433 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $830K.
  • William Blair & Company first reported a position in Portola Pharmaceuticals, Inc. in Q2 2016 and held it in 16 quarters.
  • William Blair & Company's Portola Pharmaceuticals, Inc. position peaked at $4.8M in Q1 2019.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on William Blair & Company's 13F filing for Q2 2020, filed 12 Aug 2020.